key: cord-1036825-d4g53m49 authors: Du, J.; Chu, E.; Zhang, D.; Lu, C. M.; Zhang, A.; Sha, M. Y. title: A High-throughput Anti-SARS-CoV-2 IgG Testing Platform for COVID-19 date: 2020-07-27 journal: nan DOI: 10.1101/2020.07.23.20160804 sha: cc43c0a50902535ba753ccadcc7b646520c6ee4b doc_id: 1036825 cord_uid: d4g53m49 Background: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection. Objective: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection. Results: Clinical agreement studies were performed in 77 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 42.86% (95% CI: 9.90% to 81.59%), 55.56% (95% CI: 21.20% to 86.30%), and 96.72% (95% CI: 88.65% to 99.60%) for samples collected on 0-7 days, 8-14 days, and [≥]15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23% (95% CI: 95.53% to 99.52%). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. Conclusion: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up the anti-SARS-CoV-2 IgG testing. A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously provisionally named 2019 novel coronavirus or 2019-nCoV), has been identified as the source of a pneumonia disease (COVID-19) outbreak started in Wuhan China in late 2019 (1) and has caused a global pandemic. This virus is a single-stranded RNA virus with high sequence overlap to SARS-CoV. It contains nearly 29,900 nucleotides and has at least 14 open reading frames (ORFs): ORF1ab, spike (S), ORF3a, envelope (E), membrane (M), ORF8, and nucleocapsid (N) (2) . A recent study demonstrated that both IgM and IgG antibodies were detectable 5 days after onset in all 39 patients with SARS-CoV-2 infection (3) . The median day of seroconversion for both IgG and IgM was 13 days post symptom onset (4) . Serological testing can help detect PCR-negative COVID-19 cases, especially for cases with high clinical suspicion but more than 7 days post symptom onset (5) . Other clinical uses include epidemiologic survey of COVID-19 seroprevalence and identifying suitable subjects who are referred for donating convalescent plasma for potential therapeutic use. Serological testing may also help guide return-to-work decisions. Although many commercial testing products have been developed or are under development now, there are unmet needs for the sensitive and high throughput serological testing kits under the current global COVID-19 pandemic situation. Herein, we reported the performance evaluation of the QuantiVirus™ anti-SARS-CoV-2 IgG test which is a two-step immunoassay using Luminex platform to detect anti-SARS-CoV-2 spike protein 1 (S1) receptor-binding domain (RBD) IgG antibody in human serum or plasma specimens. Validation of the test was conducted using COVID-19 negative and positive samples on both Luminex 200 and MAGPIX ® instruments. The test takes approximately 3 hours per run with a 96-well plate capable of testing 92 patient samples. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 27, 2020. . https://doi.org/10.1101/2020.07.23.20160804 doi: medRxiv preprint Principle of the assay was shown in Figure 1 . Recombinant spike protein 1 (S1) RBD was covalently coupled to the surface of MagPlex ® Microspheres (magnetic beads) via a carbodiimide linkage using xMAP ® Antibody Coupling (AbC) kit. S1 RBD protein coated magnetic beads and human specimens were mixed and incubated at room temperature for 1 hour. The IgG antibodies present in human specimens against S1 RBD protein (the antigen) will bind the coated magnetic beads. After washing, PE conjugated anti-human IgG antibody was added to the reaction mixture and incubated at room temperature for 0.5 hour. After washing, PE fluorescence of each well in a 96-well microplate was measured on Luminex 200 or MAGPIX ® instrument for Median Fluorescence Intensity (MFI). Interpretation of the testing results was performed by calculating the MFI ratio of each sample to the average MFI of two blank wells. To evaluate the clinical performance of the QuantiVirus TM Anti-SARS-CoV-2 IgG Test, 226 COVID-19 negative samples and 77 COVID-19 positive samples were tested and evaluated for NPA and PPA. Cross-reactivity was evaluated using serum or plasma samples which are positive for IgG antibodies to the following pathogens: HIV, HAV, HBV, RSV, CMV EBV, Rubella, Influenza A, and Influenza B. Class specificity was evaluated by spiking anti-SARS-CoV-2 RBD antibody IgG isotype and IgM isotype into a negative serum sample, respectively. Within-run precision (repeatability) was evaluated by testing negative sample and positive sample in 21 or 24 replicates. Between-run precision was evaluated by testing negative sample and positive sample on five separate runs (3~4 replicates per run). For interference testing, hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10mM) were spiked into four serum samples, respectively, and the MFI was compared with the control samples. For precision evaluations, coefficient of variation (CV) was calculated as the ratio of the standard deviation (SD) to the mean. For interference testing, the samples spiked with hemoglobin or EDTA were All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 27, 2020. Table 2 ). Cross-reactivity of the QuantiVirus TM Anti-SARS-CoV-2 IgG Test was evaluated by using serum or plasma samples which are positive for IgG antibodies to the pathogens such as Influenza A or B (listed in Table 3 ). The result indicates that no cross-reactivity was found in any of the samples tested. Hemoglobin (200 mg/dL) was spiked into four serum samples to test the potential interfering effect of high-level hemoglobin which might be present in hemolysis and other conditions. Bilirubin (2 mg/dL) was spiked into four serum samples to test the potential interfering effect of high-level bilirubin in the blood which might be caused by liver dysfunction such as hepatitis and cirrhosis. Lastly, EDTA (10mM) was spiked into four serum samples to test the potential interfering effect of EDTA which is the anticoagulant used in EDTA blood collection tubes. Table 3 , the difference in the fluorescence signal (MFI) between the control samples and the samples spiked with hemoglobin, bilirubin or EDTA was all ≤ 11.5% which is acceptable to the test and no false negative or false positive results were observed. Therefore, hemoglobin, bilirubin and EDTA do not have significant interfering effect on QuantiVirus TM Anti-SARS-CoV-2 IgG Test at the tested concentrations. Within-run precision (repeatability) was evaluated by testing negative sample and positive sample in 21 or 24 replicates. Between-run precision was evaluated by testing negative sample and positive sample on five separate runs (3~4 replicates per run). As shown in Supplementary Table 4 and Table 5 , the average All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 27, 2020. . https://doi.org/10.1101/2020.07.23.20160804 doi: medRxiv preprint (Supplementary Table 1 , sample UCSF H). Since this was one patient sample testing, we cannot exclude the possibility of saliva as SARS-CoV-2 antibody detection. Further development effort is ongoing. Heat-inactivation is an effective means of destroying many types of virus to protect the safety of laboratory workers. It is also a standard procedure in diagnostic laboratories to conduct neutralization test for the purpose of inactivation of complement. Previous other virus studies suggested that serum heat inactivation and optimal dilution enhance WNV E-MIA sensitivity by eliminating the complement interference, thereby detecting low-titer anti-WNV antibodies during early and late phases of infection (15) . Recently, two groups have reported that heat-inactivation of blood samples at 56 for 30 minutes does not obviously affect the results of immunochromatography and chemiluminescent immunoassay for detection of SARS-COV-2 antibodies (16, 17) . However, heat-inactivation cannot be used in fluorescence immunochromatography for SARS-CoV-2 antibody detection because negative samples became positive after heat-inactivation (16) , which is consistent with our results that heat-inactivation significantly increased the MFI for all the samples tested and the negative plasma sample became false positive. In conclusion, we have successfully developed a reliable high-throughput immunoassay for qualitative detection of anti-SARS-CoV-2 IgG antibody. The assay was validated with COVID19 positive samples as well as negative samples obtained from healthy donors on both Luminex 200 and MAGPIX ® instruments. We believe that this assay will help to determine the infection status of COVID19 and the true scope of the pandemic. It may be used to guide return-to-work decisions. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 27, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 27, 2020. . https://doi.org/10.1101/2020.07.23.20160804 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 27, 2020. . https://doi.org/10.1101/2020.07.23.20160804 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 27, 2020. . https://doi.org/10.1101/2020.07.23.20160804 doi: medRxiv preprint Negative serum sample with spiked human IgG isotype (2.5 µg/mL) 824 840 832 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 27, 2020. . https://doi.org/10.1101/2020.07.23.20160804 doi: medRxiv preprint A Novel Coronavirus from Patients with Pneumonia in China First Case of 2019 Novel Coronavirus in the United States Laboratory diagnosis of emerging human coronavirus infectionsthe state of the art Antibody responses to SARS-CoV-2 in patients with COVID-19 Report from the American Society for Microbiology COVID-19 International Summit Comparison of Luminex® 200™ to MAGPIX® using the Poultry Serology Assay Technical Notes Assay Techniques and Test Development for COVID-19 Diagnosis Serology testing for COVID-19 Immunoglobulin M for Acute Infection: True or False? Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in High similarity of IgG antibody profiles in blood and saliva opens opportunities for saliva-based serology Effect of serum heat-inactivation and dilution on detection of anti-WNV antibodies in mice by West Nile virus E-protein microsphere immunoassay Effect of heat inactivation of blood samples on the efficacy of three detection methods of SARS-CoV-2 antibodies Impact of heat-inactivation on the detection of SARS-CoV-2 IgM and IgG antibody by ELISA All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.